Kirsch B, Smith S, Cohen J, et al. - Researchers conducted this phase II, multicenter, randomized, controlled, double-blinded study to assess the topical treatment of axillary hyperhidrosis with the novel anticholinergic sofpironium bromide. Participants in the study were randomized to 1 of 3 dosages or vehicle, with daily treatment for 42 days. Data reported that 70%, 79%, 76%, and 54% of participants in the 5%, 10%, 15%, and vehicle groups showed ≥1-point improvement in Hyperhidrosis Disease Severity Measure-Axillary at the end of therapy. According to findings,  sofpironium bromide gel produced significant reductions in the severity of hyperhidrosis and had an acceptable safety profile. The majority of adverse events related to treatment were mild or moderate.